

**ADAP Crisis Task Force**  
**Final Update on Negotiation with Industry Partners**  
**June 30, 2016**

On March 31, 2016, the ADAP Crisis Task Force (Task Force) met with AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck & Co. to negotiate pricing of curative direct acting antiviral (DAA) hepatitis C (HCV) medications. These negotiations are part of the Task Force's commitment to ensuring that all AIDS Drug Assistance Program (ADAP) clients in need of HCV treatment are able to access these breakthrough, life-saving, curative treatments. Manufacturers offer substantial discounts to ADAPs for HIV medications, and the Task Force encouraged them to offer comparable discounts on curative HCV treatments.

The Task Force has concluded negotiations with industry partners regarding access to hepatitis C treatments. As previously announced, the Task Force reached substantial agreements with AbbVie and Merck. On June 23, the Task Force reached agreement with Bristol-Myers Squibb on the price of Daklinza.

Gilead Sciences refused to negotiate with ADAPs on a price for Sovaldi and Harvoni. ADAPs can access these medications at the 340B price, which represents at least a 23.1% discount off of the Average Manufacturers Price (AMP). However, even at the 340B price, the Gilead HCV treatments are excessively more expensive than the negotiated prices of other companies.

The recent negotiations were a critical first step in establishing affordable prices for curative, DAA HCV treatments for ADAPs. The Task Force hopes that these agreements will be a catalyst for broader access to HCV treatment for individuals co-infected with HIV and HCV.

**ADAP Crisis Task Force**

Arizona - California - Florida - Illinois - Maryland - Massachusetts  
New York - North Carolina - Tennessee - Texas - Virginia - Washington